Avagard is a drug owned by 3m Health Care Inc. It is protected by 6 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 03, 2016. Details of Avagard's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US7081246 | Stable hydroalcoholic compositions |
Aug, 2016
(8 years ago) |
Expired
|
| US5897031 | Dispenser for antimicrobial liquids |
Jun, 2016
(8 years ago) |
Expired
|
| US6623744 | Stable hydroalcoholic compositions |
Jun, 2015
(9 years ago) |
Expired
|
| US6534069 | Stable hydroalcoholic compositions |
Jun, 2015
(9 years ago) |
Expired
|
| US6090395 | Stable hydroalcoholic compositions |
Jun, 2015
(9 years ago) |
Expired
|
| US7566460 | Stable hydroalcoholic compositions |
Jun, 2015
(9 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Avagard's patents.
Latest Legal Activities on Avagard's Patents
Given below is the list of recent legal activities going on the following patents of Avagard.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical | 27 Aug, 2018 | US7081246 |
| Maintenance Fee Reminder Mailed Critical | 05 Mar, 2018 | US7081246 |
| Expire Patent Critical | 28 Aug, 2017 | US7566460 |
| Post Issue Communication - Certificate of Correction | 16 May, 2012 | US7566460 |
| Patent Issue Date Used in PTA Calculation Critical | 28 Jul, 2009 | US7566460 |
| Recordation of Patent Grant Mailed Critical | 28 Jul, 2009 | US7566460 |
| Email Notification Critical | 09 Jul, 2009 | US7566460 |
| Issue Notification Mailed Critical | 08 Jul, 2009 | US7566460 |
| Application Is Considered Ready for Issue Critical | 25 Jun, 2009 | US7566460 |
| Dispatch to FDC | 25 Jun, 2009 | US7566460 |
US patents provide insights into the exclusivity only within the United States, but Avagard is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Avagard's family patents as well as insights into ongoing legal events on those patents.
Avagard's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Avagard's generic launch date based on the expiry of its last outstanding patent is estimated to be Aug 03, 2016 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Avagard Generics:
There are no approved generic versions for Avagard as of now.
About Avagard
Avagard is a drug owned by 3M Health Care Inc. It is used for skin disinfection in surgical and healthcare personnel. Avagard uses Alcohol; Chlorhexidine Gluconate as an active ingredient. Avagard was launched by 3M in 2001.
Approval Date:
Avagard was approved by FDA for market use on 07 June, 2001.
Active Ingredient:
Avagard uses Alcohol; Chlorhexidine Gluconate as the active ingredient. Check out other Drugs and Companies using Alcohol; Chlorhexidine Gluconate ingredient
Treatment:
Avagard is used for skin disinfection in surgical and healthcare personnel.
Dosage:
Avagard is available in solution form for topical use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 61%;1% | SOLUTION | Over the counter | TOPICAL |